Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 50%High 1 · 16.7%

Serious adverse events · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.27 [0.87, 1.87]
10 studies · 1585 participants
Moderate

Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.3 [1.04, 1.63]
9 studies · 1497 participants
Moderate

Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.14 [1.03, 1.27]
12 studies · 1655 participants
High

Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse event · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.07 [0.82, 1.4]
7 studies · 1138 participants
Moderate